AMR Knoxville in respiratory syncytial virus vaccine clinical trials

AMR Knoxville in respiratory syncytial virus vaccine clinical trials


When disease strikes a community, it’s easy to feel helpless. But amid a new wave of RSV in Tennessee, older adults take an extraordinary step to stop it.  

A Knoxville clinical trial could lead to the approval of a vaccine decades in the making.

Research company AMR Knoxville is taking part in vaccine clinical trials for respiratory syncytial virus, commonly known as RSV, for adults. RSV is a highly contagious, seasonal respiratory disease that primarily afflicts older adults and young children.

Older adults in Knoxville can help make it happen. The company is enrolling volunteers now. 

RSV test positivity rates began to climb across Tennessee between mid-May and June. The disease is usually quiet this time of year, but test positivity rates peaked at 35% in mid-June, almost as if it was the normal wintertime infection season. 



Source link

Add a Comment

Your email address will not be published.